Genitourinary Cancers

Nivolumab plus cabozantinib was safe and active for the real-world frontline treatment of patients with advanced RCC.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Fecal microbiota transplantation extended median PFS with first-line pembrolizumab plus axitinib in metastatic RCC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Darlifarnib plus cabozantinib showed preliminary activity and safety across dose levels in cabozantinib-treated ccRCC.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Cabozantinib was active with no new safety signals in second-line advanced RCC after treatment with frontline checkpoint inhibitor–based therapy.

Drs Park and Beckermann discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium.

Neil Mendhiratta, MD, MS, discusses the treatment landscape for patients with kidney cancer during Kidney Cancer Awareness Month.

Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.

Drs Armstrong and Tawagi spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.

Ulka Vaishampayan, MD, FASCO, discusses different novel therapies in development for renal cell carcinoma.

Toni K. Choueiri, MD, discusses new data with adjuvant belzutifan plus pembrolizumab for the treatment of patients with clear cell RCC.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In a recent Peer Exchange, experts discussed RCC management and treatment sequencing considerations ahead of ASCO GU 2026.

OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

The FDA has granted priority review to the sNDA seeking the approval of belzutifan plus pembrolizumab in ccRCC.

The addition of palbociclib to belzuitfan was not associated with improved responses in pretreated clear cell renal cell carcinoma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.